Supplemental Figures 1 through 10 from PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability

Supplemental Figure 1. PAX3 Fusion in enhancer chromatin states. Supplemental Figure 2. Integration of Topological Domain Boundaries and RNA Expression Datasets Enable Discovery of Novel PAX3-FOXO1 Target Genes. Supplemental Figure 3. MYC and MYCN Expression, Enhancers and Super Enhancers in RMS Cell Lines and Primary Tumors, compared to Normal Skeletal Muscle and Myogenic Samples. Supplemental Figure 4. Genome-wide binding of PAX3-FOXO1, MYOD, MYOG and MYCN and their Functional Interdependence. Supplemental Figure 5. BRD4 at PAX3-FOXO1 Enhancers Predicts Presence of Looping Machinery and Increased Gene Expression. Supplemental Figure 6. Molecular Sensitivity Landscape of PAX3-FOXO1 RMS cells. Supplemental Figure 7. JQ1 potency across RMS cell lines and xenograft cultures. Supplemental Figure 8. Depletion of BET bromodomains in FP-RMS. Supplemental Figure 9. Impact of JQ1 on PAX3-FOXO1 target genes and PAX3-FOXO1 stability. Supplemental Figure 10. Validation of PAX3-FOXO1 Driven ALK SE Luciferase Contruct and In Vivo Efficacy of JQ1.